Congenital Bleeding Disorders amid the COVID-19 pandemic: Open questions and recommendations.
Acta Biomed
; 91(3): e2020028, 2020 09 07.
Artículo
en Inglés
| MEDLINE | ID: covidwho-761249
ABSTRACT
This article reviews the current knowledges of congenital bleeding disorders (CBD) amid the COVID-19 pandemic. It appears that CBD is not associated with higher risk of getting COVID-19 and so the prevalence of COVID-19 among them seems not higher compared to the general population. In absence of specific therapeutic recommendations, it is essential to make a correct assessment of the risk of haemorrhage/thrombosis. Based on expert opinion, strategies for outpatient management include adherence to prescribed regimens, telemedicine, and communication about COVID-19 in patients with CBD. More data should be also collected to better characterize the impact of COVID-19 on patients with CBD. The current findings encourage further studies to determine the prevalence of SARS-CoV2 infection in CBD patients to understand more fully the burden of this novel pathogen and to develop adequate preventive measures against this infection.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Telemedicina
/
Guías como Asunto
/
Infecciones por Coronavirus
/
Manejo de la Enfermedad
/
Trastornos de la Coagulación Sanguínea Heredados
/
Pandemias
/
Betacoronavirus
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Acta Biomed
Asunto de la revista:
Medicina
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS